Indigo Child Bx1 by Massmedicalstrains
Indica-dominant hybrids × Sativa-dominant hybrids
Indigo Child Bx1 is a hybrid cannabis strain meticulously developed by MassMedicalStrains, aiming for a harmonious balance between indica and sativa genetics. This strain is recognized for its complex sensory profile and well-rounded effects, making it suitable for both recreational and therapeutic users.
Appearance
Indigo Child Bx1 buds are visually striking, characterized by a vibrant combination of deep purple and green hues. They are densely formed and covered in a generous layer of trichomes, giving them a frosty appearance. The abundant pistils add a contrasting aesthetic to the dense, resinous buds.
Aroma & Flavor
The aroma of Indigo Child Bx1 is layered, starting with pungent, earthy, and spicy notes. As it develops, floral, berry, and citrus undertones emerge, creating an inviting and complex scent. The flavor mirrors this complexity, offering a rich medley of berry and herbal notes on the inhale, followed by lingering spicy and earthy tastes on the exhale.
Effects
This strain typically induces a balanced experience, beginning with cerebral stimulation that can lead to feelings of euphoria and enhanced mental clarity. These uplifting effects are then complemented by a profound sense of physical relaxation, creating a well-rounded and consistent outcome for users.
Terpenes & Cannabinoids
Indigo Child Bx1 is noted for its robust cannabinoid profile, with THC levels generally ranging from 18% to 25% and CBD around 1% to 3%. Key terpenes identified include myrcene, limonene, and caryophyllene, which contribute to its distinct aroma, flavor, and therapeutic properties. The balanced cannabinoid and terpene distribution is believed to contribute to its synergistic effects.
Origins & Lineage
Developed by MassMedicalStrains, Indigo Child Bx1 is the result of meticulous breeding focused on achieving a balanced indica/sativa heritage. The strain's genetic lineage combines traditional landrace varieties with modern refinements, resulting in a hybrid with approximately equal indica and sativa characteristics. Initial development for this strain began around 2017, with the final phenotype established by 2019.